Note 8 - Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

	Three Months Ended June 30, 2018
	Clinical Development			Device			Total
Net revenues	$	46,000		$	1,958,000		$	2,004,000
Cost of revenues		49,000			1,592,000			1,641,000
Gross profit		(3,000	)		366,000			363,000
Operating expenses		28,408,000			2,460,000			30,868,000
Operating loss	$	(28,411,000	)	$	(2,094,000	)	$	(30,505,000	)
Depreciation and amortization	$	69,000		$	105,000		$	174,000
Impairment Charges	$	27,202,000		$	--		$	27,202,000
Stock-based compensation expense	$	122,000		$	41,000		$	163,000

	Three Months Ended June 30, 2017
	Clinical Development			Device		Total
Net revenues	$	113,000		$	3,388,000	$	3,501,000
Cost of revenues		111,000			1,862,000		1,973,000
Gross profit		2,000			1,526,000		1,528,000
Operating expenses		1,899,000			1,361,000		3,260,000
Operating loss	$	(1,897,000	)	$	165,000	$	(1,732,000	)
Depreciation and amortization	$	110,000		$	62,000	$	172,000
Stock-based compensation expense	$	100,000		$	81,000	$	181,000

	Six Months Ended June 30, 2018
	Clinical Development			Device			Total
Net revenues	$	108,000		$	3,763,000		$	3,871,000
Cost of revenues		120,000			3,036,000			3,156,000
Gross profit		(12,000	)		727,000			715,000
Operating expenses		29,588,000			4,889,000			34,477,000
Operating loss	$	(29,600,000	)	$	(4,162,000	)	$	(33,762,000	)
Depreciation and amortization	$	137,000		$	196,000		$	333,000
Impairment Charges	$	27,202,000		$	--		$	27,202,000
Stock-based compensation expense	$	220,000		$	80,000		$	300,000
Goodwill	$	500,000		$	781,000		$	1,281,000
Total assets	$	12,808,000		$	10,435,000		$	23,243,000

	Six Months Ended June 30, 2017
	Clinical Development			Device			Total
Net revenues	$	266,000		$	6,487,000		$	6,753,000
Cost of revenues		235,000			3,613,000			3,848,000
Gross profit		31,000			2,874,000			2,905,000
Operating expenses		3,880,000			2,920,000			6,800,000
Operating loss	$	(3,849,000	)	$	(46,000	)	$	(3,895,000	)
Depreciation and amortization	$	226,000		$	131,000		$	357,000
Stock-based compensation expense	$	251,000		$	177,000		$	428,000